Wednesday, November 14, 2012


       The neurobiologic and clinical events leading to the development of clear-cut AD are now being clarified.

     Emphasis in therapeutic trials is increasingly focused on strategies for preventing the development and progression of AD.
     Screening tools that can be used both in routine clinical practice and in research studies may play an important role in the development and effective use of these new therapies.

No comments: